Vistin Pharma ASA (LTS:0RAM) Cyclically Adjusted Price-to-FCF: (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RAM Vistin Pharma ASA LTS:0RAM
63 GF Score
Price kr19.00
GF Value kr23.74
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Vistin Pharma ASA  (LTS:0RAM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Vistin Pharma ASA Cyclically Adjusted Price-to-FCF Related Terms


Vistin Pharma ASA Cyclically Adjusted Price-to-FCF Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Cyclically Adjusted Price-to-FCF Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vistin Pharma ASA Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0RAM vs ZTS, UTHR, VTRS: Cyclically Adjusted Price-to-FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistin Pharma ASA Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vistin Pharma ASA's Cyclically Adjusted Price-to-FCF falls into.


LTS:0RAM
63GF Score
Vistin Pharma ASA LTS:0RAM
Cyclically Adjusted Price-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Vistin Pharma ASA's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Vistin Pharma ASA's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.697/141.5800*141.5800
=0.697

Current CPI (Jun. 2026) = 141.5800.

Vistin Pharma ASA Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 0.974 104.200 1.323
201612 0.961 104.400 1.303
201703 -1.377 105.000 -1.857
201706 0.634 105.800 0.848
201709 -1.559 105.900 -2.084
201712 0.757 106.100 1.010
201803 -1.106 107.300 -1.459
201806 -0.674 108.500 -0.879
201809 -0.064 109.500 -0.083
201812 -0.224 109.800 -0.289
201903 -0.427 110.400 -0.548
201906 -0.194 110.600 -0.248
201909 0.333 111.100 0.424
201912 0.474 111.300 0.603
202003 -0.058 111.200 -0.074
202006 -3.676 112.100 -4.643
202009 -0.251 112.900 -0.315
202012 -0.499 112.900 -0.626
202103 0.233 114.600 0.288
202106 -0.018 115.300 -0.022
202109 -0.139 117.500 -0.167
202112 -0.488 118.900 -0.581
202203 -0.506 119.800 -0.598
202206 -1.049 122.600 -1.211
202209 0.021 125.600 0.024
202212 -0.153 125.900 -0.172
202303 0.527 127.600 0.585
202306 0.524 130.400 0.569
202309 -0.011 129.800 -0.012
202312 0.599 131.900 0.643
202403 -0.274 132.600 -0.293
202406 0.156 133.800 0.165
202409 0.777 133.700 0.823
202412 0.854 134.800 0.897
202503 0.010 136.100 0.010
202506 0.066 137.800 0.068
202509 0.534 138.500 0.546
202512 0.774 139.100 0.788
202603 -0.216 141.030 -0.217
202606 0.697 141.580 0.697

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr19.00 is trading 20% below its estimated GF Value™ of kr23.74. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Cyclically Adjusted Price-to-FCF:
  • GF Value™: kr23.74 vs. price of kr19.00 (20% below fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
63GF Score

Get the complete analysis for LTS:0RAM

Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr19.00
Price
kr23.74
GF Value